On May 24, 2023, investment bank HC Wainwright & Co. reiterated their coverage of the biotech company Entrada Therapeutics (NASDAQ: TRDA) with a recommendation to “Buy.”
Their projected price forecast indicates a potential increase of 64.64%.
As of May 11, 2023, the average one-year price target for Entrada Therapeutics is $21.93, with the highest projection at $26.25 and the lowest at $18.18. This represents an increase of 64.64% from its most recent closing price of $13.32.
For a list of companies with the largest price target upside, check out our leaderboard.
The projected annual revenue for Entrada Therapeutics is $0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -$3.90.
What does the fund sentiment look like?
92 funds or institutions reported positions in Entrada Therapeutics, an increase of 14 owners or 17.95% in the last quarter. The average portfolio weight for all funds dedicated to TRDA is 0.57%, a decrease of 11.72%. Total shares owned by institutions increased in the last three months by 0.96% to 24,953,000 shares.
What are other shareholders doing?
According to recent filings, Baker Bros. Advisors holds 4,866,000 shares, or 14.66% of the company. Mpm Asset Management holds 4,426,000 shares, or 13.33% of the company. 5AM Venture Management holds 4,408,000 shares, or 13.28% of the company. Price T Rowe Associates holds 2,984,000 shares, or 8.99% of the company, having decreased its portfolio allocation in TRDA by 1.20% over the last quarter. Meanwhile, Redmile Group holds 1,832,000 shares, or 5.52% of the company, having increased its portfolio allocation in TRDA by 12.38% over the last quarter.
For key filings regarding this company, visit Fintel.
The opinions expressed here are solely those of the author and do not necessarily represent the views of Nasdaq, Inc.
